Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Oyster Point Pharma Inc
(NQ:
OYST
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 30, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
11.06 (41)
Ask (Size)
11.17 (20)
Prev. Close
11.17
Today's Range
N/A - N/A
52wk Range
N/A - N/A
Shares Outstanding
26,014,621
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Health Care Becomes Most Overweighted Sector As Hedge Funds Crowd Into Magnificent 7
February 21, 2024
Goldman Sachs' Hedge Fund Trend Monitor highlights concentration in mega-caps, with optimism in AI and health care.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
The 7 Best Crypto and Stocks to Buy as Christmas Gifts This Year
December 21, 2022
These stocks to buy as Christmas gifts provide a number of reasons for investors to rejoice this holiday season.
Via
InvestorPlace
Performance
More News
Read More
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
December 18, 2022
Via
InvestorPlace
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST
December 07, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Why Viatris Stock Is Jumping Today
November 07, 2022
Via
The Motley Fool
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2022
From
Oyster Point Pharma, Inc.
Via
GlobeNewswire
Better Dividend Stock: AbbVie or Viatris?
November 26, 2022
Via
The Motley Fool
Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 10, 2022
From
Oyster Point Pharma, Inc.
Via
GlobeNewswire
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST
November 08, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Oyster Point Pharma, Inc. (Nasdaq - OYST), Benefitfocus, Inc. (Nasdaq - BNFT), Abiomed, Inc. (Nasdaq - ABMD), Atlas Corp. (NYSE - ATCO)
November 08, 2022
From
Brodsky & Smith LLC
Via
GlobeNewswire
Cigna To $335? Plus This Analyst Slashes PT On Six Flags Entertainment By 25%
November 08, 2022
Via
Benzinga
Spirit AeroSystems, Oyster Point Pharma, Snap And Other Big Gainers From Monday
November 08, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022
November 08, 2022
Via
Benzinga
Dow Surges 400 Points; Crude Oil Down 1%
November 07, 2022
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
November 07, 2022
Via
Benzinga
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
November 08, 2022
Via
Benzinga
Analyzing Oyster Point Pharma's Short Interest
November 07, 2022
Via
Benzinga
Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session
November 07, 2022
Via
Benzinga
Dow Jumps Over 200 Points; Verve Therapeutics Shares Plummet
November 07, 2022
Via
Benzinga
Oyster Point Pharma (NASDAQ: OYST) Enters Into Agreement to be Acquired by Viatris (NASDAQ: VTRS) For $11 Per Share Plus CVR Up to $2.00 Per Share
November 07, 2022
Via
Spotlight Growth
Viatris Bolsters Its Ophthalmology Franchise With Oyster Point Pharma Deal, Shares Surge
November 07, 2022
Via
Benzinga
Viatris (VTRS) Stock Pops 17% on Acquisition News
November 07, 2022
Via
InvestorPlace
US Stocks Mixed; Dow Rises Over 50 Points
November 07, 2022
Via
Benzinga
OYST Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Oyster Point Pharma, Inc. Is Fair to Shareholders
November 07, 2022
From
Halper Sadeh LLC
Via
Business Wire
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
November 07, 2022
From
Oyster Point Pharma, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.